Drug Profile
Somatostatin 14 - RELIEF THERAPEUTICS Holding
Latest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator mondoBIOTECH
- Developer RELIEF THERAPEUTICS Holding
- Class Antineoplastics; Cyclic peptides; Pituitary hormone release inhibiting hormones
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for preclinical development in Hepatitis-B in Switzerland
- 20 Sep 2016 Somatostatin 14 is available for licensing as of 20 Sep 2016. http://www.relieftherapeutics.com/further-opportunities/
- 20 Sep 2016 Preclinical trials in Hepatitis B in Switzerland (unspecified route)